Center for Scientific Review; Notice of Closed Meetings, 4834-4835 [2023-01474]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
4834
Federal Register / Vol. 88, No. 16 / Wednesday, January 25, 2023 / Notices
These engineered antibodies ultrapotently neutralize >12 variants of
SARS–CoV–2, including the highly
transmissible BA.4 and BA.5
subvariants of Omicron, as shown in a
pseudovirus neutralization assay. These
engineered antibodies target 3 distinct
epitopes in the receptor binding domain
of the spike protein and function by
blocking ACE2 binding. These
engineered antibodies are not impacted
by spike mutations that knockout
binding to other therapeutic antibodies,
including E484K, N439K, Y453F, L452R
and K417N. Several of the engineered
antibodies are able to simultaneously
bind to the spike protein and are
compatible for use in combination
therapies. In in vitro assays, these
combinations were shown to decrease
the appearance of escape mutants
suggesting the potential to mitigate
resistance development when used as
combination therapy. Additionally,
these engineered antibodies are better
suited for manufacturing than the
parental antibodies.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications:
• Treatment of SARS–CoV–2 infection
Competitive Advantages:
• Ultra-potent neutralization of
currently identified SARS–CoV–2
variants including Omicron
subvariants
• Combinations show the potential to
mitigate resistance
• Improved manufacturability relative
to parental antibodies
• Mechanism of Action—These
antibodies bind to block ACE2
receptor binding to the SARS CoV–2
spike protein
Development Stage: Preclinical
Research.
Inventors: John Misasi (VRC, NIAID),
Lingshu Wang (VRC, NIAID), John
Mascola (VRC, NIAID), Nancy Sullivan
(VRC, NIAID), Misook Choe (VRC,
NIAID), Richard Alan Koup (VRC,
NIAID), Man Chen, (VRC, NIAID),
Tongqing Zhou (VRC, NIAID), Peter
Kwong (VRC, NIAID), Wei Shi (VRC,
NIAID), Yi Zhang (VRC, NIAID), Eun
Sung Yang (VRC, NIAID).
Publications: None.
Intellectual Property: HHS Reference
Number E–185–2022 includes U.S.
Provisional Patent Application Number
63/404,473 filed September 7, 2022.
Licensing Contact: To license this
technology, please contact Amy F.
Petrik, Ph.D., 240–627–3721;
amy.petrik@nih.gov.
VerDate Sep<11>2014
19:12 Jan 24, 2023
Jkt 259001
Dated: January 19, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2023–01418 Filed 1–24–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Group; Modeling and Analysis of Biological
Systems Study Section.
Date: February 21–22, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Zarana Patel, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 496–9295, zarana.patel@
nih.gov.
Name of Committee: Oncology 1—Basic
Translational Integrated Review Group;
Cancer Genetics Study Section.
Date: February 21–22, 2023.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Juraj Bies, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4158, MSC 7806, Bethesda, MD
20892, (301) 435–1256, biesj@mail.nih.gov.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group; Clinical Neuroscience and
Neurodegeneration Study Section.
Date: February 22–23, 2023.
Time: 8:30 a.m. to 6:00 p.m.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: The Westin Georgetown, 2350 M
Street NW, Washington, DC 20037.
Contact Person: Jordan M. Moore, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1002A1,
Bethesda, MD 20892, (301) 451–0293,
jordan.moore@nih.gov.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Cardiovascular Differentiation and
Development Study Section.
Date: February 22, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sara Ahlgren, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, RM 4136,
Bethesda, MD 20892, (301) 435–0904,
sara.ahlgren@nih.gov.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Therapeutic Development and
Preclinical Studies Study Section.
Date: February 22–23, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health.
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Richard D. Schneiderman,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4138,
Bethesda, MD 20817, 301–402–3995,
richard.schneiderman@nih.gov.
Name of Committee: Oncology 1—Basic
Translational Integrated Review Group;
Tumor Host Interactions Study Section.
Date: February 22–23, 2023.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Angela Y. Ng, Ph.D., MBA,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 710–C,
MSC 7806, Bethesda, MD 20892, (301) 435–
1715, nga@csr.nih.gov.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Biobehavioral Mechanisms of
Emotion, Stress and Health Study Section.
Date: February 22–23, 2023.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Brittany L. Mason-Mah,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000A,
E:\FR\FM\25JAN1.SGM
25JAN1
Federal Register / Vol. 88, No. 16 / Wednesday, January 25, 2023 / Notices
Bethesda, MD 20892, (301) 594–3163,
masonmahbl@mail.nih.gov.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Integrative Myocardial Physiology/
Pathophysiology A Study Section.
Date: February 22–23, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Abdelouahab Aitouche,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4222,
MSC 7814, Bethesda, MD 20892, 301–435–
2365, aitouchea@csr.nih.gov.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel; Training in
Veterinary and Comparative Medicine.
Date: February 22, 2023.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Megan Lynne Goodall,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–8334, megan.goodall@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: January 20, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01474 Filed 1–24–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
VerDate Sep<11>2014
16:55 Jan 24, 2023
Jkt 259001
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; Fostering Mental,
Emotional, and Behavioral (MEB) Health
Among Children in School Settings:
Opportunities for Multisite Trials of
Complementary and Integrative Health
Interventions (Clinical Trial Optional).
Date: February 17, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Center for Complementary
and Integrative, Democracy II, 6707
Democracy Blvd., Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Marta V. Hamity, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, Division of Extramural Activities,
NCCIH/NIH, 6707 Democracy Boulevard,
Suite 401, Bethesda, MD 20892,
marta.hamity@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: January 20, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01473 Filed 1–24–23; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting of the National
Institute of Biomedical Imaging and
Bioengineering Special Emphasis Panel.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; P41 NCBIB Review
B–SEP.
Date: April 5–7, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Frm 00037
Fmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, DEM
II, Suite 920, 6707 Democracy Blvd.,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ruixia Zhou, MD,
Scientific Review Officer, National Institute
of Biomedical Imaging and Bioengineering,
National Institutes of Health, 6707
Democracy Blvd., Suite 957, Bethesda, MD
20817, (301) 496–4773, zhour@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, National Institute of
Biomedical Imaging and Bioengineering,
National Institutes of Health.)
Dated: January 20, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–01472 Filed 1–24–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID FEMA–2023–0002; Internal
Agency Docket No. FEMA–B–2304]
Changes in Flood Hazard
Determinations
Federal Emergency
Management Agency, Department of
Homeland Security.
ACTION: Notice.
AGENCY:
BILLING CODE 4140–01–P
PO 00000
4835
Sfmt 4703
This notice lists communities
where the addition or modification of
Base Flood Elevations (BFEs), base flood
depths, Special Flood Hazard Area
(SFHA) boundaries or zone
designations, or the regulatory floodway
(hereinafter referred to as flood hazard
determinations), as shown on the Flood
Insurance Rate Maps (FIRMs), and
where applicable, in the supporting
Flood Insurance Study (FIS) reports,
prepared by the Federal Emergency
Management Agency (FEMA) for each
community, is appropriate because of
new scientific or technical data. The
FIRM, and where applicable, portions of
the FIS report, have been revised to
reflect these flood hazard
determinations through issuance of a
Letter of Map Revision (LOMR), in
accordance with Federal Regulations.
The currently effective community
number is shown in the table below and
must be used for all new policies and
renewals.
DATES: These flood hazard
determinations will be finalized on the
dates listed in the table below and
revise the FIRM panels and FIS report
in effect prior to this determination for
the listed communities.
SUMMARY:
E:\FR\FM\25JAN1.SGM
25JAN1
]]>Agencies
[Federal Register Volume 88, Number 16 (Wednesday, January 25, 2023)]
[Notices]
[Pages 4834-4835]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-01474]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Bioengineering Sciences & Technologies
Integrated Review Group; Modeling and Analysis of Biological Systems
Study Section.
Date: February 21-22, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Zarana Patel, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892, (301) 496-9295,
[email protected].
Name of Committee: Oncology 1--Basic Translational Integrated
Review Group; Cancer Genetics Study Section.
Date: February 21-22, 2023.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Juraj Bies, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4158, MSC 7806, Bethesda, MD 20892, (301) 435-
1256, [email protected].
Name of Committee: Brain Disorders and Clinical Neuroscience
Integrated Review Group; Clinical Neuroscience and Neurodegeneration
Study Section.
Date: February 22-23, 2023.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: The Westin Georgetown, 2350 M Street NW, Washington, DC
20037.
Contact Person: Jordan M. Moore, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1002A1, Bethesda, MD 20892, (301)
451-0293, [email protected].
Name of Committee: Cardiovascular and Respiratory Sciences
Integrated Review Group; Cardiovascular Differentiation and
Development Study Section.
Date: February 22, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sara Ahlgren, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, RM 4136, Bethesda, MD 20892, (301) 435-0904,
[email protected].
Name of Committee: Cardiovascular and Respiratory Sciences
Integrated Review Group; Therapeutic Development and Preclinical
Studies Study Section.
Date: February 22-23, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health. Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Richard D. Schneiderman, Ph.D., Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4138, Bethesda, MD 20817, 301-
402-3995, [email protected].
Name of Committee: Oncology 1--Basic Translational Integrated
Review Group; Tumor Host Interactions Study Section.
Date: February 22-23, 2023.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Angela Y. Ng, Ph.D., MBA, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 710-C, MSC 7806, Bethesda, MD
20892, (301) 435-1715, [email protected].
Name of Committee: Biobehavioral and Behavioral Processes
Integrated Review Group; Biobehavioral Mechanisms of Emotion, Stress
and Health Study Section.
Date: February 22-23, 2023.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Brittany L. Mason-Mah, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000A,
[[Page 4835]]
Bethesda, MD 20892, (301) 594-3163, [email protected].
Name of Committee: Cardiovascular and Respiratory Sciences
Integrated Review Group; Integrative Myocardial Physiology/
Pathophysiology A Study Section.
Date: February 22-23, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Abdelouahab Aitouche, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4222, MSC 7814, Bethesda, MD
20892, 301-435-2365, [email protected].
Name of Committee: Center for Scientific Review, Special
Emphasis Panel; Training in Veterinary and Comparative Medicine.
Date: February 22, 2023.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Megan Lynne Goodall, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-8334,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: January 20, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-01474 Filed 1-24-23; 8:45 am]
BILLING CODE 4140-01-P
